COVID-19 Immunity and Post-Infection Response
Research activity includes COVID-19 infection and infectious diseases of the respiratory system, with attention to the durability of humoral immunity and cellular immunity after infection and treatment with monoclonal antibodies. The clinical focus also covers the effect of prior vaccination status on immune response.
- Antibody response
- T-cell response
- Revaccination timing
These studies are centered in Rome and reflect ongoing interest in immune recovery after SARS-CoV-2 infection.
COVID-19 Pneumonia and Hospital Care
Another area of interest is hospitalized COVID-19 pneumonia in patients who do not require high oxygen support, including those with and without previous anti-COVID-19 vaccination. The work examines adjunctive therapy alongside standard care in the inpatient setting.
- Hospitalized patients
- Respiratory infection management
- Host-directed therapy
This clinical area aligns with the sponsor’s involvement in acute respiratory infectious disease care.
Pulmonary Tuberculosis
The sponsor also funds research in pulmonary tuberculosis, with particular attention to bacilliferous TB and treatment support alongside standard antitubercular therapy. The therapeutic interest is directed toward improving management of active lung infection.
- Standard tuberculosis treatment
- Adjunctive therapy
- Host-targeted treatment
This area reflects sustained clinical involvement in serious mycobacterial disease.
